Consistent with previous studies, for example, IL-2 can regulate STAT4 to enhance the function of natural killer cells [53], and it can lead to the down-regulation of STAT4 protein during the treatment of lymphoma, which results in STAT4 defects and affects the therapeutic effect [54]. The gene discussed is IL2; the disease is lymphoma.